Evidence map›Paper›PMID 37147553›Full record

ArticleJournal of cancer survivorship : research and practice2024

Implementation barriers and considerations for recommending and administering the human papillomavirus (HPV) vaccination in oncology settings.

Austin R Waters, Charlene Weir, Heidi S Kramer, Karely M van Thiel Berghuijs, Yelena Wu, Deanna Kepka, Anne C Kirchhoff

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Prophylactic HPV vaccination in HPV-related gynecologic cancers: European Society of Gynecological Oncology (ESGO) prevention committee opinion.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025
    Guideline
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Austin R WatersHuntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr, Salt Lake City, UT, 84112, USA. Austin.Waters@hci.utah.edu.
Charlene WeirDepartment of Biomedical Informatics, University of Utah, Salt Lake City, UT, USA.
Heidi S KramerDepartment of Biomedical Informatics, University of Utah, Salt Lake City, UT, USA.
Karely M van Thiel BerghuijsHuntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr, Salt Lake City, UT, 84112, USA.
Yelena WuHuntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr, Salt Lake City, UT, 84112, USA.
Deanna KepkaHuntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr, Salt Lake City, UT, 84112, USA.
Anne C KirchhoffHuntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr, Salt Lake City, UT, 84112, USA.
University of Utah · USHuntsman Cancer Institute · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
CTSA UM1 Program at University of UtahUM1TR004409 · NCATS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI RACHEL HESS, Jennifer Juhl Majersik · 2023 to 2026
$21.9M
Cancer Care Quality Training ProgramT32CA116339 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ETHAN M. BASCH, Stephanie Brooke Wheeler · 2018 to 2026
$3.0M
Statewide Assessment of HPV Vaccination Among Childhood Cancer SurvivorsR03CA216174 · NCI · UNIVERSITY OF UTAH · PI KEPKA, DEANNA LEE, KIRCHHOFF, ANNE C · 2018 to 2019
$228k
NCATS NIH HHS UM1 TR004409NCI NIH HHS P30 CA042014NCI NIH HHS R03 CA216174NCI NIH HHS T32 CA116339
6 · The paper itself

Abstract

backgroundSurvivors of childhood and adolescent cancer experience low human papillomavirus (HPV) vaccination rates-a crucial form of cancer prevention. Oncology provider recommendations may increase young survivors HPV vaccine intent, but HPV vaccination is not typically provided in the oncology setting. Thus, we explored the implementation barriers of providing the HPV vaccine in oncology.

methodsWe interviewed oncology providers in a variety of specialty areas about their perceptions of the HPV vaccine and to explore barriers to recommending and administering the vaccine in their clinics. Interviews were audio recorded, quality checked, and thematically analyzed. Emergent themes were then mapped onto the Capability, Opportunity, Motivation, and Behavior (COM-B) Model and the Theoretical Domains Framework.

resultsA total of N=24 oncology providers were interviewed. Most provided direct clinical care (87.5%) and most commonly specialized in pediatric oncology (20.8%), medical oncology (16.7%), bone marrow transplant (16.7%), and nurse coordination (16.7%). Two themes emerged within each COM-B domain. Capability: 1) educational barriers to HPV vaccination and 2) complicated post treatment HPV vaccination guidelines. MOTIVATION: 1) perceived importance of HPV vaccine and 2) concern about blurred scope of practice. OPPORTUNITY: 1) hospital administration and time concern barriers and 2) clinical workflow integration concerns.

conclusionImplementing HPV vaccination in the oncology setting has the potential to increase HPV vaccination rates among young survivors. Multi-level barriers to providing the HPV vaccine in the oncology setting were identified by participants. Leveraging existing implementation strategies may be an effective way to mitigate provider identified barriers and increase vaccination rates.

Indexed as

Medical OncologyPapillomavirus InfectionsPapillomavirus VaccinesVaccinationAdolescentAdultAttitude of Health PersonnelCancer SurvivorsChildFemaleHealth Knowledge, Attitudes, PracticeHuman Papillomavirus VirusesHumansMaleNeoplasmsPapillomavirus VaccinesAYA cancer survivorsHPV vaccineImplementation sciencePediatric cancer survivors

Identifiers

PMID37147553
PMCPMC10629381
OpenAlexW4372334397

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.